Pfizer has announced the launch of a new clinical study of its experimental antiviral treatment for severe forms of Covid-19. This new test phase concerns a drug that will be taken as soon as the first symptoms appear.
This mid-stage study will test the drug PF-07321332 in up to 2,660 healthy participants aged 18 and over living with someone with a symptomatic form of Covid-19, a statement from the pharmaceutical giant.
According to Pfizer’s R&D president, Mikael Dolsten, the fight against this pandemic requires effective treatment to be administered to people who are positive or otherwise exposed to the virus, in addition to the action of vaccines that strengthen immunity.
And to emphasize that this treatment will help to hinder the virus before it replicates on a large scale in the body, and will prevent people with severe forms.
As a reminder, Pfizer has also launched another study for the treatment of Covid-19 in symptomatic adult patients who are not hospitalized.
Note that several pediatric trials have shown that the Pfizer vaccine is “safe” and “robust” in children aged 5 to 11, although at a lower dose than that received by adults.
– .
